NCT05526248 2026-03-11
ARAMON
Bayer
Phase 2 Completed
Clinical Trials
58 trialsNCT05730712 2026-02-06
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT03338790 2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2 Completed
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02203695 2025-10-28
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03939689 2025-10-14
ARROW
Progenics Pharmaceuticals, Inc.
Phase 2 Completed
NCT05081193 2025-09-22
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02007512 2025-09-02
Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Pfizer
Phase 2 Completed
NCT02430480 2025-07-16
Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT06312670 2025-05-29
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02278185 2025-05-11
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Phase 2 Completed
NCT04332744 2025-05-11
ZZ-First
MedSIR
Phase 2 Completed
NCT03314324 2025-04-17
ODENZA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT02091960 2025-04-04
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT02684227 2025-03-19
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04869488 2025-01-24
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT01889238 2024-12-13
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Pfizer
Phase 2 Completed
NCT01650194 2024-12-10
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
Astellas Pharma Inc
Phase 2 Completed
NCT01288911 2024-12-06
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT01534052 2024-12-06
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
Astellas Pharma Inc
Phase 2 Completed
NCT02799745 2024-12-06
ENACT
Astellas Pharma Inc
Phase 2 Completed
NCT02124668 2024-11-21
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Astellas Pharma Inc
Phase 2 Completed
NCT04207255 2024-09-25
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Medical University of South Carolina
Phase 2 Completed
NCT02689427 2024-09-19
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03336983 2024-08-01
BonEnza
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Completed
NCT02676986 2024-07-05
ARB
Queen Mary University of London
Phase 2 Completed
NCT02453009 2024-05-30
CHEIRON
Santa Chiara Hospital
Phase 2 Completed
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT01867333 2023-09-26
Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01974765 2023-04-28
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02225704 2023-04-06
Radium-223 in Combination With Enzalutamide
Cancer Trials Ireland
Phase 2 Completed
NCT03464201 2023-02-22
GREKO III
Grupo EspaƱol de Tumores HuƩrfanos e Infrecuentes
Phase 2 Completed
NCT02268175 2022-04-19
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02814968 2022-04-14
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
The European Uro-Oncology Group
Phase 2 Completed
NCT02815033 2022-04-14
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
The European Uro-Oncology Group
Phase 2 Completed
NCT02601014 2022-02-03
STARVE-PC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02346578 2021-09-16
Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.
Osaka City University
Phase 2 Completed
NCT02953860 2021-05-14
Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
University of Colorado, Denver
Phase 2 Completed
NCT02407054 2021-05-11
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
Eli Lilly and Company
Phase 2 Completed
NCT03103724 2021-04-26
EXCALIBUR
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT03418324 2020-12-30
Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT02286921 2020-11-06
Transformer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02199197 2020-10-30
Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
University of Utah
Phase 2 Completed
NCT02064582 2020-10-12
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT01875250 2020-09-16
Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02125357 2020-08-07
Sequencing Abiraterone and Enzalutamide in mCRPC
British Columbia Cancer Agency
Phase 2 Completed
NCT02384382 2020-05-05
A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
Pfizer
Phase 2 Completed
NCT01946165 2019-12-06
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02288936 2019-09-24
PREMIERE
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT02034552 2019-07-23
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
Bayer
Phase 2 Completed